Editorial Material
Oncology
Cedric Rossi, Rene-Olivier Casasnovas
Summary: Novel targeted approaches have significantly improved the prognosis of patients with relapsed/refractory Hodgkin lymphoma, especially with the use of inhibitors like Nivolumab and pembrolizumab.
EUROPEAN JOURNAL OF CANCER
(2022)
Editorial Material
Hematology
Peter W. M. Johnson
Summary: The study shows that treating relapsed or refractory HL with PD-1 antibody nivolumab has a high response rate, making it an attractive option for second-line therapy.
Review
Oncology
Yujie Zhang, Zhichao Xing, Li Mi, Zhihui Li, Jingqiang Zhu, Tao Wei, Wenshuang Wu
Summary: Classical Hodgkin lymphoma, the most common type of HL, mainly affects people in certain age groups. A significant proportion of patients with refractory or relapsed cHL do not respond well to treatment. Exploring new predictive strategies and treatment measures may help improve the cure rate for these patients.
FRONTIERS IN ONCOLOGY
(2022)
Review
Immunology
Jennifer E. Agrusa, Emily R. Egress, Eric J. Lowe
Summary: ALCL is the most common mature T-cell non-Hodgkin lymphoma in children/adolescents, and improved therapies are needed. Brentuximab vedotin, an anti-CD30 antibody-drug conjugate, has shown safety and efficacy in clinical trials for ALCL in both pediatric and adult populations. Future studies should investigate combination therapies with brentuximab vedotin and other targeted agents.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Heather A. Lillemoe, Roberto N. Miranda, Loretta J. Nastoupil, Mark W. Clemens, Kelly K. Hunt
Summary: Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare lymphoma that arises in response to textured-surface breast implants. It typically presents as swelling around the implant after breast reconstruction or cosmetic augmentation, but can also manifest as invasive masses or enlarged lymph nodes. There is currently limited surgical guidance for patients with more aggressive BIA-ALCL presentations.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Hematology
Sanjal H. Desai, Michael A. Spinner, Kevin David, Veronika Bachanova, Gaurav Goyal, Brad Kahl, Kathleen Dorritie, Jacques Azzi, Vaishalee P. Kenkre, Sally Arai, Cheryl Chang, Brendon Fusco, Nuttavut Sumransub, Haris Hatic, Raya Saba, Uroosa Ibrahim, Elyse Harris, Harsh Shah, Jacob Murphy, Stephen Ansell, Deepa Jagadish, Victor Orellana-noia, Catherine Diefenbach, Siddharth Iyenger, K. C. Rappazzo, Rahul Mishra, Yun Choi, Grzegorz S. Nowakowski, Ranjana H. Advani, Ivana N. Micallef
Summary: This multicenter retrospective study found that salvage therapies with checkpoint inhibitor (CPI)-based regimens had superior event-free survival (EFS) and progression-free survival (PFS) compared to conventional chemotherapy and other salvage regimens, supporting the use of CPI-based regimens in relapsed/refractory transplant-eligible classic Hodgkin lymphoma (R/R cHL) in the pre-autologous stem cell transplant (ASCT) setting.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Oncology
Yuqin Song, Quanli Gao, Huilai Zhang, Lei Fan, Jianfeng Zhou, Dehui Zou, Wei Li, Haiyan Yang, Ting Liu, Quanshun Wang, Fangfang Lv, Haiyi Guo, Xia Zhao, Dan Wang, Pei Zhang, Yidi Wang, Lei Wang, Tengfei Liu, Yun Zhang, Zhirong Shen, Jane Huang, Jun Zhu
Summary: This study presents the extended 3-year follow-up of tislelizumab in patients with relapsed/refractory cHL, showing long-term benefits and a favorable safety profile.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Paul J. Broeckelmann, Horst Mueller, Sarah Gillessen, Xiaoqin Yang, Larissa Koeppel, Veronika Pilz, Patricia Marinello, Peter Kaskel, Monika Raut, Michael Fuchs, Peter Borchmann, Andreas Engert, Bastian von Tresckow
Summary: Evaluation of rrHL patterns after first-line treatment revealed that high-dose chemotherapy and autologous stem-cell transplantation resulted in 10-year progression-free and overall survival rates of 48.2% and 59.4% respectively. Factors such as age and treatment failure significantly influenced patient survival rates.
Article
Oncology
Fulvio Massaro, Nathalie Meuleman, Dominique Bron, Marie Vercruyssen, Marie Maerevoet
Summary: This retrospective study evaluated the efficacy of a combination of brentuximab vedotin and pembrolizumab as a bridge treatment to autologous stem cell transplantation (ASCT) in relapsed/refractory Hodgkin lymphoma (HL) patients. The results showed that this combination therapy is highly effective for high-risk patients.
Article
Hematology
Michael A. Spinner, R. A. Sica, John S. Tamaresis, Ying Lu, Cheryl Chang, Robert Lowsky, Matthew J. Frank, Laura J. Johnston, David B. Miklos, Lori S. Muff Ly, Robert S. Negrin, Andrew R. Rezvani, Parveen Shiraz, Judith A. Shizuru, Wen -Kai Weng, Michael S. Binkley, Richard T. Hoppe, Ranjana H. Advani, Sally Arai
Summary: The treatment landscape of relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL) has significantly changed over the past decade with the use of brentuximab vedotin (BV) and PD-1 inhibitors. A study comparing outcomes from 2011 to 2020 with those from 2001 to 2010 showed improved overall survival (OS) and increased postprogression survival in the modern era, attributed to the use of BV and PD-1 inhibitors. Factors associated with inferior progression-free survival (PFS) included age ≥45 years, primary refractory disease, and lack of complete remission pre-AHCT, while receipt of a PD-1 inhibitor-based regimen pre-AHCT was associated with superior PFS.
Review
Medicine, General & Internal
Pauline Brice, Eric de Kerviler, Jonathan W. Friedberg
Summary: Classical Hodgkin lymphoma is a relatively common lymphoma that is generally considered highly curable with standard first-line chemotherapy and radiotherapy, although some patients may not be cured or may experience late toxic effects leading to premature death. Recent changes in the gold standard of chemotherapy, now often including immunotherapy in relapse settings, have further impacted treatment outcomes.
Review
Oncology
Walter Hanel, Alex F. Herrera, Narendranath Epperla
Summary: The treatment landscape of classical Hodgkin lymphoma has significantly changed in the past 20 years, with improvements in patient management and increased complexity in treatment approaches. By incorporating new drugs and adjusting treatment sequences, long-term remission can be achieved, and treatment advancements are expected to continue with ongoing clinical trials.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2022)
Review
Surgery
Hani Naga, Joseph A. Mellia, Marten N. Basta, Martin P. Morris, Adrienne N. Christopher, Frank M. Campbell, Katie Sommers, Howard Levinson, Jonas A. Nelson, John P. Fischer
Summary: This study assessed current treatment strategies for breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL). The results showed that current guidelines focus on the treatment of local disease and reduce nonsurgical interventions. Patients with advanced BIA-ALCL have higher rates of recurrence and mortality.
PLASTIC AND RECONSTRUCTIVE SURGERY
(2022)
Review
Oncology
Huimin Ma, Xin Li, Meng Lin, Kebing Lv, Mingzhi Zhang, Xiaolong Wu
Summary: The current standard treatment for relapsed or refractory HL is salvage chemotherapy followed by ASCT, but it may not be successful for all patients. New treatment options including targeted therapy and immunotherapy, such as BV and anti-PD-1 antibodies, have shown effectiveness in treating these patients. BV and anti-PD-1 antibodies can be used alone or in combination with other chemotherapy regimens for rescue, consolidation, and second-line treatment of R/R HL.
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
(2021)
Article
Oncology
Deepa Jagadeesh, Steve Horwitz, Nancy L. Bartlett, Youn Kim, Eric Jacobsen, Madeleine Duvic, Meredith Little, William Trepicchio, Keenan Fenton, Matthew Onsum, Julie Lisano, Ranjana Advani
Summary: This article examines the relationship between CD30 expression level and clinical response to brentuximab vedotin. The analysis showed that CD30 expression alone cannot predict the clinical benefit of brentuximab vedotin.
Review
Oncology
Inigo Terren, Ane Orrantia, Idoia Mikelez-Alonso, Joana Vitalle, Olatz Zenarruzabeitia, Francisco Borrego
Article
Immunology
Joana Vitalle, Laura Tarancon-Diez, Maria R. Jimenez-Leon, Inigo Terren, Ane Orrantia, Cristina Roca-Oporto, Luis Lopez-Cortes, Ezequiel Ruiz-Mateos, Olatz Zenarruzabeitia, Francisco Borrego
Review
Biochemistry & Molecular Biology
Joana Vitalle, Inigo Terren, Ane Orrantia, Agurtzane Bilbao, Pedro M. Gamboa, Francisco Borrego, Olatz Zenarruzabeitia
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2020)
Article
Multidisciplinary Sciences
Joana Vitalle, Inigo Terren, Leire Gamboa-Urquijo, Ane Orrantia, Laura Tarancon-Diez, Miguel Genebat, Manuel Leal, Ezequiel Ruiz-Mateos, Francisco Borrego, Olatz Zenarruzabeitia
SCIENTIFIC REPORTS
(2020)
Article
Multidisciplinary Sciences
Ane Orrantia, Inigo Terren, Alicia Izquierdo-Lafuente, Juncal A. Alonso-Cabrera, Victor Sanda, Joana Vitalle, Santiago Moreno, Maria Tasias, Alasne Uranga, Carmen Gonzalez, Juan J. Mateos, Juan C. Garcia-Ruiz, Olatz Zenarruzabeitia, Francisco Borrego
Letter
Allergy
Christina L. Pranger, Judit Fazekas-Singer, Verena K. Koehler, Isabella Pali-Schoell, Alessandro Fiocchi, Sophia N. Karagiannis, Olatz Zenarruzabeitia, Francisco Borrego, Erika Jensen-Jarolim
Article
Hematology
Inigo Terren, Ane Orrantia, Joana Vitalle, Gabirel Astarloa-Pando, Olatz Zenarruzabeitia, Francisco Borrego
SEMINARS IN HEMATOLOGY
(2020)
Article
Immunology
Olatz Zenarruzabeitia, Gabirel Astarloa-Pando, Inigo Terren, Ane Orrantia, Raquel Perez-Garay, Iratxe Seijas-Betolaza, Javier Nieto-Arana, Natale Imaz-Ayo, Silvia Perez-Fernandez, Eunate Arana-Arri, Francisco Borrego
Summary: This study analyzed the immune system status of patients with different severity of COVID-19, finding that severe cases exhibit higher activation levels in various T cell subsets, increased expression of immune markers in cytotoxic cells, and accumulation of dysfunctional monocytes. The study also showed a strong association between immune cell alterations and clinical signs of severity.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Multidisciplinary Sciences
Inigo Terren, Ane Orrantia, Alba Mosteiro, Joana Vitalle, Olatz Zenarruzabeitia, Francisco Borrego
Summary: NK cells acquire memory-like properties following stimulation with IL-12, IL-15 and IL-18, and these cytokine-induced memory-like NK cells have shown promising potential in cancer immunotherapy. NK cells modulate their metabolism in response to cytokine-stimulation, with a link between metabolism and cellular functions.
SCIENTIFIC REPORTS
(2021)
Review
Oncology
Ane Orrantia, Inigo Terren, Gabirel Astarloa-Pando, Olatz Zenarruzabeitia, Francisco Borrego
Summary: NK cells are important components of the innate immune system that play a key role in tumor immunosurveillance. While the therapeutic potential of NK cells in allogeneic HSCT is well recognized, their significance and effects on outcomes in autologous HSCT are less understood. This review summarizes the diverse functions and roles of NK cells in different HSCT settings.
Review
Pharmacology & Pharmacy
Idoia Mikelez-Alonso, Susana Magadan, Africa Gonzalez-Fernandez, Francisco Borrego
Summary: NK cells are lymphocytes with potent antitumor and antiviral functions, exhibiting memory-like responses. Various NK cell-based immunotherapies have been developed, with nanotechnology considered as an attractive option to enhance NK cell effector functions.
ADVANCED DRUG DELIVERY REVIEWS
(2021)
Review
Pharmacology & Pharmacy
Susana Magadan, Idoia Mikelez-Alonso, Francisco Borrego, Africa Gonzalez-Fernandez
Summary: Recent studies have shown that innate immune cells can exhibit changes in their functional programs after infection or vaccination, leading to trained immunity or innate immune memory, distinct from the specific memory immune response by B and T lymphocytes. The review mainly focuses on myeloid cells in trained immunity, pathogen recognition in evolution, and techniques for studying epigenetic reprogramming and metabolic rewiring. Nanomaterials offer a promising avenue to understand trained immunity and can be modified to modulate immune responses.
ADVANCED DRUG DELIVERY REVIEWS
(2021)
Article
Immunology
Ane Orrantia, Inigo Terren, Gabirel Astarloa-Pando, Carmen Gonzalez, Alasne Uranga, Juan J. Mateos-Mazon, Juan C. Garcia-Ruiz, Marta Rinon, Mercedes Rey, Silvia Perez-Fernandez, Olatz Zenarruzabeitia, Francisco Borrego
Summary: AutoHSCT in MM patients leads to significant changes in NK cell subsets and phenotype, with patients showing lower frequencies of the mature NKG2A-CD57+ NK cell subset experiencing better clinical outcomes. This suggests that the degree of NK cell maturation post-autoHSCT affects the disease progression and treatment outcomes in MM patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Meeting Abstract
Allergy
C. L. Pranger, J. F. Singer, V. K. Koehler, I. Pali-Schoell, A. Fiocchi, S. N. Karagiannis, O. Zenarruzabeitia, F. Borrego, E. Jensen-Jarolim
Article
Biochemical Research Methods
Ane Orrantia, Inigo Terren, Joana Vitalle, Gabirel Astarloa-Pando, Olatz Zenarruzabeitia, Francisco Borrego